Douglas K. Rovira, M.D.

42% fewer Medicare Part D claims than the average hematology & oncology physician in 2024

513 Medicare Part D claims for 142 beneficiaries, against an average of 877 among the 10,784 providers of this specialty who prescribed in Part D. Brand-name drugs were 15% of claims. 36 claims were for opioids.

Most prescribed

1. Anastrozole58 claims
2. Prochlorperazine Maleate37 claims
3. Dexamethasone32 claims
4. Hydroxyurea29 claims
5. Prednisone25 claims
6. Ondansetron Odt20 claims

Source: CMS Medicare Part D Prescribers by Provider and Drug, 2024 (data.cms.gov). Part D covers prescriptions for Medicare patients only; drugs with fewer than 11 claims are not published.

The practice group's MIPS final score for 2023 (Medicare payment program): 88.2 of 100

The Merit-based Incentive Payment System score is reported for the practice group, not for one clinician alone. Four categories are weighted into the final score; the average among 454,083 clinicians with a measured score was 83.5.

Source: CMS Quality Payment Program, MIPS performance year 2023, group reporting; category weights for 2023 (qpp.cms.gov).

Industry payments in 2024: $542.54

23 payments; by number, the most common kind was food and beverage; the largest payer was Merck Sharp & Dohme LLC. The 8,560 providers of this specialty with any payment received $7,481.41 on average. Payments are reported by manufacturers, not by the provider, and are not a sign of wrongdoing.

Source: CMS Open Payments, program year 2024 (openpaymentsdata.cms.gov); average among providers of this specialty with at least one payment.

Bills Medicare through 2 group practices

1. St Vincent HospitalSanta Fe, NM
2. University OF ChicagoChicago, IL

Source: CMS Doctors and Clinicians National Downloadable File (the group practices a clinician bills Medicare through) (data.cms.gov).